Related references
Note: Only part of the references are listed.Predictive Factors of Non-Response to Vismodegib in Locally Advanced Basal-Cell Carcinoma
Helene Marescassier et al.
DERMATOLOGY (2021)
Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study
R. Dummer et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular, and superficial) of high-risk or locally advanced basal cell carcinoma, in an open-label, prospective case series clinical trial
Scott W. Fosko et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Basal cell carcinoma Epidemiology; pathophysiology; clinical and histological subtypes; and disease associations
Michael C. Cameron et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study
Aleksandar Sekulic et al.
BMC CANCER (2017)
The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma
Reinhard Dummer et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC
Aleksandar Sekulic et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
Michael R. Migden et al.
LANCET ONCOLOGY (2015)